San Diego, CA -- (ReleaseWire) -- 08/22/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market:INNV), an emerging commercial stage cash flow positive pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories received the approval of the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® from the Indian FDA, The Drugs Controller General (India), and the Directorate General of Health Services to commercialize the products in India.

"We are thrilled to have received the approval to commercialize our products from the Indian FDA in a very short time due to the strength of the dossier and the clinical trials. India is our seventh country where we have our products approved and we look forward to start the commercial launch by our partner Khandelwal Labs in the very near future," said Dr. Bassam Damaj, President and CEO of Innovus Pharmaceuticals, Inc.

On September 10, 2015 Innovus Pharma entered into an exclusive marketing and distribution agreement with Khandelwal Laboratories based in India ("KLab") under which Innovus Pharma has granted to KLab an exclusive ten-year license and distribution rights to market and sell Innovus Pharma's products. These products include Zestra® to increase Female Sexual Arousal and Desire and Satisfaction, EjectDelay® for treating premature ejaculation, Sensum+® to increase penile sensitivity and Zestra Glide®, the high-viscosity water-based lubricant. If KLabs exceeds its minimum yearly orders, the agreement has two five-year term extensions. Under the agreement, the minimum orders for the first term of the agreement are over two million and six hundred thousand ($2.6M) US dollars annually.

About Zestra® and Female Sexual Interest/Arousal Disorder (FSI/AD)
Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first Natural Health Product (NHP) to receive approval for the indication of FSI/AD in Canada as an NHP. To date, the Company believes that no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger. Zestra® is currently available in the United States, Canada and Morocco.

For more information visit www.zestra.com.

About EjectDelay® and Premature Ejaculation
EjectDelay® is an over-the-counter ("OTC") U.S. Food and Drug Administration and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for treatment of premature ejaculation. The drug typically works within minutes of application to the glans of the penis.

In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes. For more information visit www.ejectdelay.com.

Premature ejaculation ("PE") is the most common sexual dysfunction reported by men but is still under-diagnosed and under-treated. PE can happen at any age and its prevalence is consistent across all ages. In an article in The Journal of Sexual Medicine in 2007 Sex Med 2007, D.L. Patrick, D. Rowland and M. Rothman stated, "Global studies consistently report that 20-30% of men experience PE worldwide."

About Sensum+® and Reduced Penile Sensitivity (RPS)
Sensum+® is a patented blend of essential oils and natural botanicals including rose oil, sweet almond oil, cinnamon bark oil, and other extracts. The main ingredient of Sensum+® (cinnamon oil) works by activating the Transient Receptor Potential A1 (TRPA-1) channels responsible for the heat and cold sensation of the skin and results in an increase of sensation that current users welcome and appreciate. The safety and efficacy of Sensum+® was evaluated in 2 post marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for fourteen consecutive days followed by once daily for 8 weeks and as needed thereafter.

Reduced penile sensitivity is a major problem associated with many diseases such as hernia surgery, the use of anti-depressants, circumcision, multiple sclerosis and others. There are no approved products to treat RPS.

For more information visit www.sensumplus.com.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to:
www.innovuspharma.com
www.zestra.com
www.ejectdelay.com
www.myvesele.com
www.sensumplus.com
www.myandroferti.com
www.beyondhumantestosterone.com
www.getbeyondhuman.com
www.trybeyondhuman.com

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval of the product licenses in India. or to be compliant with the requirements of any relevant regulatory authority relating to its Products to successfully commercialize this product and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

View source version on businesswire.com: www.businesswire.com/news/home/20160819005041/en/

Contact:
Brokers and Analysts
Chesapeake Group
Kevin Holmes, 410-825-3930
info@chesapeakegp.com

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 08/05/2016 -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") http://www.innovuspharma.com (OTCQB:INNV) announced today it will release its second quarter 2016 financial results before the open of trading on Tuesday August 9, 2016 ahead of its 10-Q to be filed on August 15, 2016. The company will host a conference call at 4:15 p.m. EDT/1:15 p.m. PDT on the same day (August 9, 2016) to discuss the financial results and recent business developments.

To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers. Participant Elite Entry Number: 2157659. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally and reference Conference ID: 10091310. The replay will be available one hour after the end of the end of the conference.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to:
www.innovuspharma.com
www.zestra.com
www.ejectdelay.com
www.myvesele.com
www.sensumplus.com
www.myandroferti.com
www.beyondhumantestosterone.com
www.getbeyondhuman.com
www.trybeyondhuman.com
http://www.recalmax.com

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize its products and to achieve its other development, commercialization, meeting its sales projections, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
Tel: 410-825-3930

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Asian Counties Include Japan, Korea, Indonesia and China - PT Laras Bumi Resources Projects Close to 150,000 Units a Year

San Diego, CA -- (ReleaseWire) -- 08/04/2016 -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV) announced today it has re-appointed PT Laras Bumi Resources ("LB Resources") as its agent for the distribution of its product Zestra® to increase Female Sexual Arousal and Desire and Satisfaction in select Asian countries.  Based in Indonesia ("LB Resources") has extensive distribution in Japan, China, Indonesia and South Korea. LB Resources projects an initial ordering annual volume close to 150,000 units a year.

Prior to its acquisition by Innovus Pharma, Semprae Labs shipped over 1 million units of Zestra® to Asia.

Since Zestra® is already registered as a cosmetic in China and South Korea and is well known, the Company expects to start commercial shipments as early as September 2016.

"This partnership is an important one for the Company as it allows us to resume sales of Zestra® to multiple Asian countries where the product is already registered.  Our goal is to quickly get back to the one million units of sales a year previously achieved by the product," said Dr. Bassam Damaj, President & CEO of Innovus.

About Zestra® and FSI/AD
Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada as an NHP. To date, the Company believes that no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger. Zestra® is currently available in the United States, Canada and Morocco.

For more information visit http://www.zestra.com

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to:
www.innovuspharma.com
www.zestra.com
www.ejectdelay.com
www.myvesele.com
www.sensumplus.com
www.myandroferti.com
www.beyondhumantestosterone.com
www.getbeyondhuman.com
www.trybeyondhuman.com
www.recalmax.com

About PT Laras Bumi Resources
Established in 1987 and based in Indonesia, PT Laras Bumi Resources Food & Health Products Division has developed extensive distribution, compliance and regulatory expertise in Asia including extensive affiliations in Greater China, Korea, Japan, Russia, Asiana Indonesia and Singapore.

For more information please visit: www.lbresources.com

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize its products and to achieve its other development, commercialization, meeting its sales projections, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein.  Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
Tel: 410-825-3930

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Company in a Strong Cash Position for Product Launches and Expedited Growth

San Diego, CA -- (ReleaseWire) -- 08/01/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB:INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today, the closing of its previously announced $3 million private financing from institutional investors.

"Our ability to attract high caliber institutional investors into the Company is a testimony of to the strength of our current commercial and product pipeline and is an important step in our ongoing up-listing process" said Dr. Bassam Damaj, President & CEO of Innovus Pharma.

For more information, investors are invited to read the Form 8-K filed with the Securities and Exchange Commission ("SEC") at www.sec.gov

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to www.innovuspharma.com, www.zestra.com, www.ejectdelay.com, www.myvesele.com, www.sensumplus.com, www.myandroferti.com, www.beyondhumantestosterone.com, www.getbeyondhuman.com, www.trybeyondhuman.com, www.recalmax.com

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize its products and to achieve its other development, commercialization, meeting its sales projections, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
Tel: 410-825-3930

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Money Raised to Fast Track the Move to Being Cash Flow Positive in 2016

San Diego, CA -- (ReleaseWire) -- 07/06/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB:INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today, the closing of $1.5 million convertible promissory note investment from institutional investors. The convertible promissory notes have a $0.25 fixed conversion price and bear an interest rate of 10% and mature in 13 months.

"Our ability to raise money in such a difficult market is a testimony to the strength of the Company and its pipeline. The new capital raised will increase the current growth we are experiencing in our sales, and will fast track our goal of being cash flow positive exiting 2016 and potentially profitable exiting 2017," said Dr. Bassam Damaj, President & CEO of Innovus Pharma.

Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC and Garden State Securities, Inc. acted as placement agents for this offering.

For more information, investors are invited to read the 8K filed with the Securities and Exchange Commission (SEC) at http://www.sec.gov

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to:
www.innovuspharma.com
www.zestra.com
www.ejectdelay.com
www.myvesele.com
www.sensumplus.com
www.myandroferti.com
www.beyondhumantestosterone.com
www.getbeyondhuman.com
www.trybeyondhuman.com
http://www.recalmax.com

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize its products and to achieve its other development, commercialization, meeting its sales projections, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein.  Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC.  Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
Tel: 410-825-3930

Source: UPTICK Newsiwre

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 06/22/2016 -- SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at the underserved Female Sexual Interest Arousal Dysfunction (FSI/AD) market and Innovus Pharmaceuticals' (OTCQB:INNV) clinically proven over-the-counter treatment, Zestra®.

FSI/AD represents a sizable market that is potentially larger than the multi-billion-dollar erectile dysfunction -- or ED -- marketplace. Community studies have shown that FSI/AD affects between 25% and 63% of women with an average prevalence of 43% compared to just 31% for ED's prevalence in men. Despite the prevalence of this condition, there are no FDA approved prescription medications in the market labeled for use in treating FSI/AD. The only existing treatments are used off-label and involve a range of potential adverse side effects, as well as the use of personal lubricants and devices that may or may not be effective.

To view the SECFilings.com article examining Zestra's potential, click on the link below or copy and paste the address in your browser:  http://secfilings.com/News.aspx?title=innovus_pharma_innv_targets_underserved_multi_billion_dollar_fsi/ad_market&naid=1394

About SECFilings.com
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

For full disclosure please visit: http://secfilings.com/Disclaimer.aspx

Contact:
Paul Archie
406-862-2242
parchie@secfilings.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 06/21/2016 -- The global erectile dysfunction drug market is expected to reach $3.2 billion by 2022, according to Grand View Research Inc., with drugs like Viagra and Cialis leading the way. Through the use of nitric oxide conversion, these phosphodiesterase type 5 inhibitors (PDE5) based drugs increase blood flow to the penis and enable a natural erection to take place. The problem is that these drugs tend to lose efficacy over time with 40% of men stopping use of the drug.

In this article, we will take a look at a company that has developed an innovative, natural product that could work to complement the efficacy of erectile dysfunction drugs with a range of other benefits.

Innovus' Patented Vesele® Solution
Innovus Pharmaceuticals Inc.'s (OTCQB:INNV) Vesele® is an over-the-counter, patented dietary supplement designed to maximize the benefits of nitric oxide through the use of the amino acids L-Citrulline and L-Arginine, as well as a patented perine extract called BioPerine® to increase absorption of the two amino acids. These ingredients combine to increase nitric oxide production and enable healthy blood flow throughout the body, which in turn may increase the efficacy of drugs like Viagra or Cialis.

Nitric oxide (NO) is one of the most powerful endogenous vasodilators, which has made it a popular target in the erectile dysfunction space. In fact, the 1998 Nobel Prize in Physiology and Medicine was awarded to three Americans for their discovery of the nitric oxide molecule, in the cardiovascular system. While the amino acids help with NO production, BioPerine® inhibits CYP3A4 and P-glycoprotein enzymes to slow metabolism and increase bioavailability.

In a 72-patient U.S. clinical use study over 16 weeks, Vesele® users reported a 49.5% increase in erection hardness, a 44.5% increase in erection maintenance, a 34.6% increase in desire for sexual activity, a 34.1% increase in the ability to satisfy a partner, and a 44% increase in overall satisfaction. Figure 1 below shows a number of these benefits in relation to baseline measurements, demonstrating strong efficacy across multiple areas of sexual health.

To review the Clinical Trial Results for Men – Source: Innovus Pharma please click here.

Additional Potential Benefits
Innovus Pharma's Vesele®'s mechanism of action also opens the door to a number of other potential benefits. At its core, the company's BioPerine® technology increases the bioavailability of a range of water and fat soluble vitamins, multi-vitamins, proteins, and molecules. The company has tested the substance on other vitamins and minerals like CoQ10, selenium, vitamin C, and beta carotene with high levels of success.

To review the BioPerine® Study Results – Source: Innova Pharma please click here.

The company conducted clinical use studies that found improvements in retention of information, learning new things, tracking items, recalling words, processing information, and maintaining thoughts while distracted. These benefits suggest there may be reasons to take Vesele® beyond simply the sexual benefits thanks to the broad mechanism of action underlying the product. Figure 3 below shows the results of these studies compared to baseline results.

To review Cognitive Benefits of Vesele® - Source: Innova Pharma please click here.

Looking Ahead
Innova Pharma's Vesele® has demonstrated widespread efficacy in both improving sexual performance for men and potentially adding cognitive benefits. With many traditional erectile dysfunction drugs failing to help men over the long run, Vesele® could be a great supplement to complement the performance over time. The product has also been shown to be effective in improving female sexual health in many of the same ways.

Investors in the OTC pharmaceutical or generics space, including small-cap companies like Lannett Company Inc., Aclaris Therapeutics Inc., or TherapeuticsMD Inc., may want to take a closer look at the stock. With a market capitalization of just $13 million, the company represents a unique investment opportunity within the microcap biotech space. The company's commercial OTC portfolio extends well beyond Vesele® into many related areas and includes Zestra®, EjectDelay®, Sensum+®, Zestra Glide®, Beyond Human Testosterone Booster and Androferti®. In addition, the company has a pipeline of more than three additional products targeting other potentially lucrative markets.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to:
www.innovuspharma.com
www.zestra.com
www.ejectdelay.com
www.myvesele.com
www.sensumplus.com
www.myandroferti.com
www.beyondhumantestosterone.com
www.getbeyondhuman.com
www.trybeyondhuman.com

For more information, visit the company's website at www.innovuspharma.com.

Contact:
Brokers and Analysts
Kevin Holmes
Chesapeake Group
410-825-3930
info@chesapeakegp.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Company on Track to be Being Cash Flow Positive Exiting 2016

San Diego, CA -- (ReleaseWire) -- 06/15/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB:INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today that the Company has reduced its debt obligation by $1.5 million and also eliminated approximately $300k in derivative liabilities as of 3/31/16, resulting in a total reduction of outstanding liabilities of over $1.8 million.

"The reduction of the debt from our books and the huge reduction in liabilities is a testimony to the financial strength of the Company, and to our commitment to the goal of being cash flow positive exiting 2016 and potentially profitable exiting 2017," said Dr. Bassam Damaj, President & CEO of Innovus Pharma.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to:
www.innovuspharma.com
www.zestra.com
www.ejectdelay.com
www.myvesele.com
www.sensumplus.com
www.myandroferti.com
www.beyondhumantestosterone.com
www.getbeyondhuman.com
www.trybeyondhuman.com
www.recalmax.com

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize its products and to achieve its other development, commercialization, meeting its sales projections, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
Tel: 410-825-3930

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 06/09/2016 -- The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.

The Pfizer's Viagra Revenue – Source: Statista to view the chart please click here.

According to IMS data, Viagra accounted for over 47.0% of the total revenue in 2014. It is generally considered as the first line of treatment for erectile dysfunction. Brand loyalty and initial effectiveness are the major factors attributing for its large market share. Cialis (tadalafil) from Eli Lilly & Co. and Levitra (vardenafil) from Bayer AG are known to be the competitors for Viagra globally. Cialis (tadalafil) was approved in 2003 by the United States Food and Drug Administration as a prescription drug. Cialis is also known as "The Weekend Pill" owing to its 36-hour effectiveness.

North America constituted the largest share of approximately 55.0% in 2013 of the total erectile dysfunction market. Extension of patent exclusivity rights for Viagra (sildenafil citrate) in the U.S. till 2019 along with introduction of new erectile dysfunction drugs such as Zydena (udenafil) and Stendra/Spedra (avanafil) will be the major factors responsible for market growth during the forecast period.

Viagra and Cialis fall into the Phosphodiesterase type 5 inhibitors (PDE5) class of drugs and are currently the first line treatment for erectile dysfunction (ED), among others. PDE5 inhibitors work by increasing the blood flow to the penis through nitric oxide (NO) conversion therefore allowing a natural erection to take place. However, several published research shows that PDE5 treatments have high discontinuation rates. The study published by Carvalheira AA et al. in the highly reviewed Journal of Sexual Medicine shows that close to 40% of men on PDE5 inhibitors stop using the drugs due to loss of efficacy.

Innovus Pharmaceuticals' (OTCQB:INNV) Vesele®, currently on the U.S. market, is designed to maximize the benefits of NO. The product contains two amino acids: L-Citrulline and L-Arginine, plus a patented piperine extract called BioPerine®, that helps the body absorb these amino acids and results in higher NO production. Nitric Oxide relaxes blood vessels to allow for healthy blood flow throughout the body.

Innovus ran a 72 patient U.S. human survey use clinical trial over 16 weeks in people with low erectile dysfunction accompanying endpoints including: 1) erection hardness; 2) erection maintenance; 3) frequency of sexual encounters; and 4) desire for sexual encounters.

The results announced by the company show that Vesele® use resulted in the following:

- 49.5% increase in erection hardness

- 44.5% increase in erection maintenance

- 34.6% increase in desire for sexual activity

- 34.1% increase the ability to satisfy the partner

- 44% increase in overall satisfaction

Based on the results from Innovus' study and the similar mechanism of action of the PDE5 inhibitors and Vesele® it is conceivable that the combination of the two products might result in a higher blood flow and therefore better erections and clinical responses.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g) Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com;www.trybeyondhuman.com.

Looking Ahead
Innovus Pharmaceuticals plans to capitalize on the enormous market for erectile dysfunction with a clinically proven product with widespread distribution. Investors may want to keep an eye on the stock over the coming quarters as it expands awareness of Vesele and works to build out its other pipeline products. As it transitions to profitability, the company will likely attract the interest of a growing number of institutional investors.

For more information, visit the company's website at www.innovuspharma.com.

Contact:
Brokers and Analysts
Kevin Holmes
Chesapeake Group
410-825-3930
info@chesapeakegp.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 06/07/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCMKTS:INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories filed the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® with the Indian FDA, The Drugs Controller General (India) and the Directorate General of Health Services to commercialize the products in India.

The process is expected to take between 120 to 180 days pending any questions from the Indian government.

On September 10, 2015 Innovus Pharma entered into an exclusive marketing and distribution agreement with Khandelwal Laboratories based in India ("KLab") under which Innovus Pharma has granted to KLab an exclusive ten-year license and distribution rights to market and sell some of Innovus Pharma's products including: Zestra® to increase Female Sexual Arousal and Desire and Satisfaction, EjectDelay® for treating premature ejaculation, Sensum+® to increase penile sensitivity and Zestra Glide® the high viscosity water based lubricant. If KLab exceeds its minimum yearly orders, the agreement has two five-year term extensions. Under the agreement, the minimum orders for the first term of the agreement are over two million and six hundred thousand ($2.6M) US dollars."

"We are seeing the benefits of our signed commercial partnerships for our products and we look forward to the potential approval of our four products in India. We are determined to enter yet another large market for our products to continue to boost our revenues," said Damaj. "

About Zestra® and FSI/AD 
Zestra® is a patented blend of natural oils clinically-proven in double -blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada as an NHP. To date, the Company believes that no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger. Zestra® is currently available in the United States, Canada and Morocco.

For more information visit www.zestra.com.

About EjectDelay® and Premature Ejaculation
EjectDelay® is an over-the-counter ("OTC") U.S. Food and Drug Administration and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for treatment of premature ejaculation. The drug typically works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes.

For more information visit www.ejectdelay.com.

Premature ejaculation ("PE") is the most common sexual dysfunction reported by men but is still under-diagnosed and under-treated. PE can happen at any age and its prevalence is consistent across all ages. In an article in The Journal of Sexual Medicine in 2007 Sex Med 2007, D.L. Patrick, D. Rowland and M. Rothman stated, "Global studies consistently report that 20-30% of men experience PE worldwide."

About Sensum+® and Reduced Penile Sensitivity (RPS)
Sensum+® is a patented blend of essential oils and natural botanicals including rose oil, sweet almond oil, cinnamon bark oil, and other extracts. The main ingredient of Sensum+® (cinnamon oil) works by activating the Transient Receptor Potential A1 (TRPA-1) channels responsible for the heat and cold sensation of the skin and results in an increase of sensation that current users welcome and appreciate. The safety and efficacy of Sensum+® was evaluated in 2 post marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for fourteen consecutive days followed by once daily for 8 weeks and as needed thereafter.

Reduced penile sensitivity is a major problem associated with many diseases such as hernia surgery, the use of anti-depressants, circumcision, multiple sclerosis and others. There are no approved products to treat RPS.

For more information visit www.sensumplus.com.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com;www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval of the product licenses in India. or to be compliant with the requirements of any relevant regulatory authority relating to its Products to successfully commercialize this product and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Brokers and Analysts
Kevin Holmes
Chesapeake Group
410-825-3930
info@chesapeakegp.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 06/02/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQBVentureMarket:INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that it will seek regulatory guidance from the United Kingdom's MHRA as a Reference Member State in Europe before submitting its European application for its FlutiCare™ (50mcg fluticasone propionate) 60 and 120 sprays/bottle.

The guidance is expected to take 3-4 months pending the response from the MHRA in the UK. Under a European system called the "Decentralized Procedure" (DCP), a company files its application for marketing approval of a drug in just one European country, which is designated the Reference Member State (RMS). Innovus Pharma has chosen The United Kingdom as its RMS. The RMS then evaluates the application and prepares an assessment report that is submitted to other chosen European Union countries for their consideration and approval. The entire process takes approximately 240 days. One of the major advantages of the DCP is that a company may receive identical marketing authorizations for its product in multiple chosen European Member countries at the same time.

"Submitting our application to the European Agency will be another major milestone for the Company as it will open for us a very large market for our product and increase our revenues dramatically if approved," said Damaj. "

Fluticasone propionate nasal spray is sold under the brand name of Flixonase by GSK in Europe.

In Europe, allergy is considered a public health pandemic. It affects over 150 million people, making it the continent's most prevalent chronic disease.

FlutiCare™ targets the allergic and non-allergic rhinitis – better known as "hay fever" or "stuffy nose" by the public. The company's FlutiCare™ active is the #1 nasal steroid prescribed by physicians and used by patients with more than 177 million units dispensed since 2007. According to a report by Fierce Pharma, GSK's Flonase OTC sold over $100,000MM in a short period of time from its launch, confirming the size of the market and the potential of FlutiCare™ if approved by the FDA.

About FlutiCare™
Fluticasone propionate 50 mcg spray is the No. 1 prescribed allergy treatment ingredient [1] for temporary relief of the symptoms of hay fever or upper respiratory allergies. [2]

Roughly 50 million people in the United States suffer from nasal allergies [3], and allergies take a toll on sufferers:

-Nasal allergies can lead to fatigue, sleep disturbances, learning and attention problems and impaired function at work and/or school. [4]

- In 2010, Americans with allergic rhinitis (AR) spent approximately $17.5 billion on health- related costs, lost more than 6 million work and school days and made more than 16 million visits to the doctor. [5]

- 70 percent of sufferers treat their symptoms with prescription or OTC treatments [6]; however, 50 percent of them report they are not completely satisfied with their current method of treatment. [7]

References

[1] Sur D, et al. Treatment of Allergic Rhinitis. American Family Physician. Volume 81, Number 12, June 15, 2010.

[2] American College of Allergy, Asthma and Immunology: Allergy facts. Available at http://www.acaai.org/allergist/news/Pages/Allergy_Facts.aspx. Accessed July 2014.

[3] American College of Allergy, Asthma and Immunology: Allergic diseases and cognitive impairment. Available at http://www.acaai.org/allergist/allergies/Types/rhinitis/Pages/allergic-diseases-cognitive-impairment.aspx. Accessed July 2014.

[4] Academy of Allergy and Asthma in Primary Care: National impact of allergies. Available at http://www.aaapc.us/wp-content/uploads/2013/01/National-Impact-of-Allergies.pdf. Accessed July 2014.

[5] Scadding G, Punekar Y. EAACI 2006, Abstract 742.

[6] New Survey Reveals Many Patients Want More from Their Allergy Medication. Asthma and Allergy Foundation of America. Available at: http://www.aafa.org/display.cfm?id=7&sub=92&cont=529. Accessed April 24, 2014[7] Data on hand

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval of the ANDA in the U.S. or to be compliant with the requirements of any relevant regulatory authority relating to Fluticare™, to successfully commercialize this product and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Brokers and Analysts
Kevin Holmes
Chesapeake Group
410-825-3930
info@chesapeakegp.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 06/01/2016 -- Innovus Pharmaceuticals Inc. (OTCQB:INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative, and effective over-the-counter medicine and consumer care products, plans to launch a new product into a multibillion dollar market in the near-term. After acquiring over-the-counter rights to FlutiCare™ - a leading prescription nasal steroid – in February 2015, the company expects to receive regulatory approval later this year.
 
In this article, we will take a look at the company's plans to transition FlutiCare™ from a prescription nasal steroid into an over-the-counter treatment, as well as the timeline to launch and the financial potential from the move over the coming years.

Rx to OTC Transition

FlutiCare™ is the leading nasal steroid recommended by physicians for the treatment of nasal congestion, sneezing, runny nose, and itchy nose. While GlaxoSmithKline's Rx Flonase brand has sold roughly two million units, FlutiCare™ Rx form has sold more than 177 million units, making it a clear leader in the Rx nasal steroid market. Both of these products will compete against Sanofi's Nasacort, which has been the only product on the market for a year.

In addition to competing with each other, nasal steroids compete with OTC allergy products that alleviate many of the same symptoms, including so-called "D" allergy pills like Bayer's Claritin and Johnson & Johnson's Zyrtec. While these products are popular among allergy sufferers, they aren't as effective as many Rx nasal steroids at clearing nasal-specific symptoms associated with allergies, such as a runny or stuffy nose.
 
The nasal steroid market is expected to become a $1+ billion market opportunity as these brands transition from prescription-only to over-the-counter. With 75% market share in the prescription market, FlutiCare™ is well positioned to become a clear leader in the OTC market given its efficacy and patient satisfaction if approved by the FDA. The company will initially target these existing Rx users and expand the market to include external customers over the coming years.

Time to Market

The over-the-counter Abbreviated New Drug Application (ANDA) for the product was filed with the U.S. Food & Drug Administration during the fourth quarter of 2014. In January of 2015, the FDA accepted the ANDA for review and the application has been making its way through the lengthy approval process. The good news is that ANDA applications take less time than NDA applications, since the drug already has been approved in prescription form.

According to an April 2016 investor presentation, the company anticipates approval of the new OTC ANDA during summer 2016. Should the company receive approval on the product at this time, management plans to launch the product during late Q4 2016 or early Q1 of 2017 through a variety of different channels.

It is worth noting that the FDA's approval of the ANDA could be a significant catalyst for the stock in the near-term. The commercialization of FlutiCare™ is a significant long-term catalyst for the stock as revenues accelerate. The unique combination of a short- and long-term catalyst might make the stock appealing to investors.

Marketing Strategy

Innovus plans to launch the over-the-counter version of FlutiCare™ through both traditional retailers, such as Target, Walgreens's Drugstore, and CVS where it already has a presence in the OTC space, as well as through online channels. As the #1 nasal steroid used by Rx patients and the #1 nasal steroid prescribed by physicians, the company is well positioned to capitalize on the market opportunity and unlock significant long-term value for shareholders.
 
The company plans to launch a media campaign when the OTC indication is approved that will include television, sponsored field surveys, and print advertising among other channels. In addition, the company will market directly to healthcare professionals and pharmacists to encourage referrals for the product. And finally, the company has developed attractive in-store advertising to target consumers at the point of purchase.

FlutiCare™ is also ideally suited for online distribution given its potential for customer loyalty and relatively high per unit retail value that provides margin cushion. The company plans on using the FlutiCare™ brand website as a content marketing hub for allergic rhinitis sufferers, while leveraging a dynamic e-mail platform and detailed analytics to ensure a high return on investment for its marketing efforts and enable real-time improvements.

Looking Ahead

About Innovus Pharmaceuticals
Innovus Pharmaceuticals is uniquely positioned to capitalize on the over-the-counter nasal steroid market with its leading product and existing distribution. With a market worth more than a billion dollars per year at its fingertips, the company could see significant revenue over the near-term if FlutiCare™ obtains an approval from the U.S. Food and Drug Administration later this year – a milestone that could also catalyze the stock.

For more information, visit the company's website at www.innovuspharma.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 05/31/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles. Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.

"This is a major milestone for the Company as manufacturing of a drug is one of the biggest hurdles in the ability of companies to market products," said Dr. Bassam Damaj, President & CEO of the Company.

It addition to the manufacturing of the product, the Company previously announced that it has established over 30,000 stores in the United States as Vendors of Record in addition to the major wholesale drug distributors in anticipation of the FDA's decision.

"Innovus has successfully launched multiple products in the U.S. and we have the needed expertise and know how to make it happen for FlutiCare™ if approved by the FDA," continued Dr. Damaj.

"While the ANDA is under review, the manufacturing agreement is in place and the vendors of record are established. We await the FDA's decision and are fully prepared to go full speed with the sales and marketing if the drug is approved," said Dr. Damaj.

FlutiCare™ targets the allergic and non-allergic rhinitis – better known as "hay fever" or "stuffy nose" by the general public. The company's FlutiCare™ active is the #1 nasal steroid prescribed by physicians and used by patients with more than After dispensing more than 177 million units since 2007, According to a report by Fierce Pharma, GSK's Flonase OTC sold over $100,000M in a short period of time from its launch confirming the size of the market and the potential of FlutiCare™ if approved by the FDA.

About FlutiCare™
Fluticasone propionate 50 mcg spray is the No. 1 prescribed allergy treatment ingredient [1] for temporary relief of the symptoms of hay fever or upper respiratory allergies.[2]

Roughly 50 million people in the United States suffer from nasal allergies [3], and allergies take a toll on sufferers:

-Nasal allergies can lead to fatigue, sleep disturbances, learning and attention problems and impaired function at work and/or school. [4]

- In 2010, Americans with allergic rhinitis (AR) spent approximately $17.5 billion on health- related costs, lost more than 6 million work and school days and made more than 16 million visits to the doctor. [5]

- 70 percent of sufferers treat their symptoms with prescription or OTC treatments [6]; however, 50 percent of them report they are not completely satisfied with their current method of treatment.[7]

References

[1] Sur D, et al. Treatment of Allergic Rhinitis. American Family Physician. Volume 81, Number 12, June 15, 2010.

[2] American College of Allergy, Asthma and Immunology: Allergy facts. Available at http://www.acaai.org/allergist/news/Pages/Allergy_Facts.aspx. Accessed July 2014.

[3] American College of Allergy, Asthma and Immunology: Allergic diseases and cognitive impairment. Available at http://www.acaai.org/allergist/allergies/Types/rhinitis/Pages/allergic-diseases-cognitive-impairment.aspx. Accessed July 2014.

[4] Academy of Allergy and Asthma in Primary Care: National impact of allergies. Available at http://www.aaapc.us/wp-content/uploads/2013/01/National-Impact-of-Allergies.pdf. Accessed July 2014.

[5] Scadding G, Punekar Y. EAACI 2006, Abstract 742.

[6] New Survey Reveals Many Patients Want More from Their Allergy Medication. Asthma and Allergy Foundation of America. Available at: http://www.aafa.org/display.cfm?id=7&sub=92&cont=529. Accessed April 24, 2014[7] Data on hand

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval of the ANDA in the U.S. or to be compliant with the requirements of any relevant regulatory authority relating to Fluticare™, to successfully commercialize this product and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:

Brokers and Analysts
Kevin Holmes

Chesapeake Group
410-825-3930

info@chesapeakegp.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Innovus Eligible to Receive up to $6.2 Million in Upfront and Sales Milestone Payments plus Transfer Price

San Diego, CA -- (ReleaseWire) -- 05/25/2016 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCMKTS:INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases today announced today that it has entered into an exclusive license and distribution agreement with BroadMedSAL, a Lebanese company ("BroadMed") under which Innovus Pharma granted to BroadMed an exclusive license to market and sell Innovus product EjectDelay® indicated for treatment of premature ejaculation in Lebanon. Under the agreement, Innovus Pharma is eligible to receive up to $6.2 million dollars in upfront and sales milestone payments plus transfer price.

EjectDelay® is currently commercialized in the US by Innovus and in Canada under the name Uxor™ by Orimed Pharm. In addition, the Company has signed multiple commercial agreements for the product the following countries by Innovus Pharma's where the product will be registered and market by the following licensees and distributors: Elis Pharma in Turkey, Ovation Pharma in Morocco, Tabuk Pharmaceuticals for the rest of the Middle East and North Africa, OZ Biogenics in Maynmar and Vietnam.

Bassam Damaj, President and Chief Executive Officer of Innovus Pharma commented, "We are very happy about this latest commercial partnership collaboration with BroadMed with as this his agreement represents the sixth international commercial partnership for this product. This international partnership also represents the 11th such agreement for the Company and its products and its signing represents another milestone in the Company's execution of its international growth strategy to make our products commercially available in as many countries as possible."

EjectDelay will be the first product to enter this market containing benzocaine. The company is expecting to sell 20,000 to 40,000 units a year in this market once approval is received from the local Ministry of Health. Approval is expected later this year.

About EjectDelay® and Premature Ejaculation
EjectDelay® is an over-the-counter ("OTC") U.S. Food and Drug Administration and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for treatment of premature ejaculation. The drug typically works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes.

For more information visit www.ejectdelay.com and www.uxor.ca

Premature ejaculation ("PE") is the most common sexual dysfunction reported by men but is still under-diagnosed and under-treated. PE can happen at any age and its prevalence is consistent across all ages. In an article in The Journal of Sexual Medicine in 2007 Sex Med 2007, D.L. Patrick, D. Rowland and M. Rothman state, "Global studies consistently report that 20-30% of men experience PE worldwide. This means that PE is experienced at similar rates across the globe."

About BroadMed Pharma
Based in Lebanon, BroadMed is a privately held Lebanese company that markets and distributes branded generic pharmaceuticals and under-licensed products. The Company operates in 20 countries in the MENA region and has over 200 products on the market.

For more information on BroadMed, go to www.broad-med.com

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products.. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company

Contact:
Brokers and Analysts
Kevin Holmes
Chesapeake Group
410-825-3930
info@chesapeakegp.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 05/24/2016 -- Innovus Pharmaceuticals Inc. (OTCQB:INNV), a provider of over-the-counter and consumer products for men and women's health, vitality, and respiratory diseases, recently acquired Beyond Human for a cash purchase price of $630,000. The acquisition provided the company with natural testosterone booster supplements, including Beyond T Human® and Human Growth Agent HGA® that generated $2.2 million in revenue and $400,000 in profit last year.

In this article, we will take a closer look at the testosterone replacement market and why the company's recent acquisition of Beyond Human is a move in the right direction.

Testosterone Replacement

According to the National Institutes of Health, roughly five million American men do not produce enough testosterone – and that number is growing as the population ages. Men tend to experience a gradual decline in testosterone after the age of 30, which can cause fatigue, weakness, depression, and the loss of a sex drive. These issues can significantly decrease quality of life and have a profound impact on those in relationships.

To view the Testosterone Level by Age Chart please click here.

The primary treatment for these conditions is testosterone replacement through gels or patches that must be regularly applied to maintain steady testosterone levels. More recently, implantable testosterone pellets have been released into the market as a device that is implanted under the skin of the buttocks and releases the hormone over the course of three to four months – reducing the need for daily gels or patches.

The global hormone replacement therapy market is expected to reach $28.4 billion in size by 2022, according to Grand View Research. Within this market, testosterone replacement is expected to grow at an ~10% compound annual growth rate, from $2.4 billion in 2013 to $3.8 billion by 2018, with most products on the market coming from large multinational companies like AbbVie Inc. and Eli Lilly & Co., as well as from some smaller competitors.

Alternative Approaches

Beyond Human takes a different approach to testosterone boosting through a nutritional supplement rather than direct injection or a topical gel. The company's flagship Beyond T Human® contains Vitamin B6, Vitamin B12, Zinc, and a proprietary blend of Fenugreek, Eurycoma Longifolia, Rhodiola Rosea, Saw Palmetto, and Astaxanthin. Ingredients in this supplement have been published and shown to naturally boost testosterone levels without taking the hormone directly.

Vitamin B6 suppresses the synthesis of estrogen in the body and regulates androgen production, which both help increase testosterone levels. In the short-term, vitamin B12 has been shown to raise testosterone levels dramatically after injection or ingestion. And, the herbal components of the supplement include both cordycepssinensis and tribulusterrestris, which have both been shown to improve testosterone production.

Innovus Pharma could help further validate these claims by initiating studies to determine the efficacy of the Its BTH supplement as a whole product as it has with its Zestra® product or female sexual dysfunction, its Androferti® for male infertility and Vesele® for increasing blood flow. With its deep expertise in running clinical studies, the company's other men and women's health and vitality products have been extensively validated in the clinic in order to reassure customers that they're getting an effective treatment. Beyond T Human® also fits well within its existing sexual health product portfolio.

Bottom Line Impact

Beyond Human generated over $1.3 million in gross sales and approximately $300,000 in net profit during 2014, according to Innovus' press release announcing the deal. In 2015, these figures rose to $2.2 million in gross revenue and $400,000 in net profit. Management expects to grow these figures to over $3 million in gross revenue and over $600,000 in net profit once the acquisition is fully integrated into its platform over the next few years.

Management plans to grow the newly acquired assets by selling the six new Beyond Human products through its numerous international distributors. The company also plans on leveraging Beyond Human's online platform and large database of thousands of customers to cross sell its existing products, including EjectDelay®, Sensum+®, and Vesele®. These are highly complementary products that could see strong uptake from the customer base.

"The closing of the acquisition of the Beyond Human assets marks a turning point in Innovus Pharma revenue scale-up and we believe it should help the Company move into a cash flow positive situation followed by profitability very quickly," said Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma.

Looking Ahead

Innovus Pharma's acquisition of Beyond Human cements its position in the rapidly growing testosterone booster supplement industry and creates compelling synergies with its existing customers and distribution channels. Investors interested in the OTC pharmaceutical space, including companies like Aclaris Therapeutics Inc. or Teligent Inc. may want to take a closer look at the stock.

For more information, visit the company's website at www.innovuspharma.com.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.

For further information on INNV please visit www.upticknewswire.com

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products.. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company

Innovus Pharmaceuticals, Inc.
Reuven Rubinson
Vice President of Finance
rreubinson@innovuspharma.com
858-964-5123

Source: https://upticknewswire.com/innovus-pharma-joins-abbvie-inc-and-eli-lilly-co-in-the-race-for-the-3-billion-testosterone-replacement-market

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 05/18/2016 -- An uplisting to a national exchange is an important goal for many small over-the-counter companies in order to gain credibility and reach a wider base of potential investors. By holding companies to a higher standard, an uplisting creates a higher level of visibility, exposure, and legitimacy for companies that are able to meet the stringent prerequisites.

For experienced executives, who have been successful with dealing with higher exchanges uplisting to the NYSE-MKT for example, is a much easier and attainable objective.

The New York Stock Exchange acquired the American Stock Exchange in 2008 and branded it the NYSE-MKT. This is an attractive exchange for high-quality micro and small-cap companies with four different listing and public shareholder standards and a number of differing combinations within. As a result, the NYSE-MKT listing requirements offers flexibility to companies operating in different market sectors.

VIEW IMAGE

The NYSE-MKT listing board also conducts a subjective review of all listing candidates looking at a number of different factors influencing investment quality, including:

- Nature of a company's business;

- Market for its products;

- Reputation of its management;

- Historical record and pattern of growth;

- Financial integrity;

- Demonstrated earnings power; and

- Future outlook

Innovus Pharma (INNV) is preparing for an uplisting to the NYSE MKT, according to its President & CEO Dr. Bassam Damaj's last conference call. The company has been experiencing significant growth that could translate into larger volume and increase in its market cap. Although a lot of OTC companies' executives state that their goal is to uplist their companies, relatively few executives actually have the expertise to accomplish the task. Uplisting a company requires more than the meeting the uplisting share price and shareholder equity requirements.

The two most important requirements are:

- Management and their previous history and expertise: Innovus Pharma management has a strong CEO who knows how to work with higher exchanges at previous companies like Apricus Biosciences (previously known as NexMed). At Apricus Biosciences, he transitioned the company from being deficient in every listing requirement with the NASDAQ exchange to being compliant in all requirements in less than a year after he took over the helm in 2009 (Source: APRI SEC filings). Under his leadership, Apricus went from $0.17 a share to over $5 and was named one of the most liquid companies NASDAQ. The company went on to be included in the Russell Microcap Index.

- Company Future Outlook: This is a very important requirement as it shows that the company is a real business with growth potential in the near term and worth being uplisted and followed by analysts. Innovus has created a solid growth model and its management is executing on its plans on a daily basis. The company has a robust product pipeline in multiple markets. It expects an ANDA action from the FDA during the summer for FlutiCare, for allergic rhinitis, one of the largest markets in the US.

Since January 2016, the Company's share price has gained 107% and it volume increased by 1100%.

The Rewards of Uplisting Are Well Worth the Effort

Once a company does manage to prove itself and satisfy uplisting requirements, the benefits are both impactful and immediate. The biggest benefit is increased visibility. Whereas a lower listing confined a company to simple over the counter exchanges between individuals, a bigger listing gives a company access to the larger institutional investors. These institutional investors can start to accumulate positions adding more credibility and liquidity, as well as, potentially, share appreciation.

Newly uplisted companies also benefit from higher trading volumes (greater liquidity). Studies from large exchanges, such as the NASDAQ, confirm that, after uplisting, companies tend to see 3-month average daily volume increase of a 132%.

In the early periods after uplisting, a company usually gets intense coverage from top analysts, thereby making the company's stock more attractive to investors. In the end, uplisting is one of the many tools a company can utilize to help create long-term shareholder value for a company with a solid management business plan.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com;www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.

For further information on INNV please visit www.upticknewswire.com

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products.. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company

Innovus Pharmaceuticals, Inc.
Reuven Rubinson
Vice President of Finance
rreubinson@innovuspharma.com 858-964-5123

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 05/16/2016 -- Innovus Pharmaceutical, Inc. (OTCQB:INNV) and Lipocine Inc. are two specialty pharmaceutical companies focused on men and women's health that have PDUFA and ANDA dates scheduled over the next few months that could significantly alter their future prospects.

Upcoming catalysts drive the stock prices of many biotech and pharmaceutical companies, such as Prescription Drug User Fee Act (PDUFA) dates or Abbreviated New Drug Application (ANDA) actions. These are scheduled dates are when the FDA makes a decision on whether or not to approve a new or a generic drug candidate.

Innovus Pharma and Lipocine each have very interesting products addressing large markets that could soon be introduced to the U.S. market following potential FDA approvals.

Innovus Pharmaceuticals, Inc. (OTCQB:INNV) is an emerging leader in OTC and consumer products for men's and women's health and vitality. The company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

The company's FlutiCare™ product candidate has an ANDA filed with the FDA and has an expected response date of July to august of 2016. With over 40 million units of nasal spray sold in the U.S. during 2014, management estimates the global market for FlutiCare™ to be $1 billion per year as it transitions Fluticasone propionate nasal spray into the over-the-counter markets.

Lipocine Inc. - Lipocine Inc. is a specialty pharmaceutical company which develops pharmaceutical products using its oral drug delivery technology in the area of men's and women's health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate low dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability, its lead product candidate, LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing, is under FDA review. Lipocine's pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase II clinical study. LPCN 1107 is in Phase I clinical study for the prevention of recurrent preterm birth.

The company's LPCN 1021 product candidate expects potential PDUFA approval on June 28, 2016. As an oral testosterone agent that's designed to replace existing therapies – typically topical creams or injections – the product could see widespread adoption as consumers look for more convenience delivery methods.

These two companies may have unrelated products under review by the FDA (Innovus Pharma's Fluticare™ is for allergic rhinitis and Lipocine's LPCN 1021 is an oral testosterone replacement), but the two companies also have a lot of commonalities:

1. Lipocine CFO Morgan Brown came out of Innovus Pharma.

2. Both companies target the testosterone market through different products with Innovus Pharma's BTH natural testosterone booster and Lipocine LPCN 1021 oral testosterone booster.

3. Management is known to turn around companies with great success.

Investors may want to keep a close eye on both of these companies as key FDA response dates approach and PDUFA and ANDA decisions could serve as key catalysts for the stock price.

For more information, visit Innovus Pharmaceuticals' website at www.innovuspharma.com and Lipocine's website at www.lipocine.com.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products.. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company

Innovus Pharmaceuticals, Inc.
Reuven Rubinson
Vice President of Finance
rreubinson@innovuspharma.com
858-964-5123

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

New leadership to move into E- commerce and potential strong revenue generation

Barrie, ON -- (ReleaseWire) -- 05/05/2016 -- Telecorp, Inc. (OTCMarkets:TLNUF) ("Telecorp" or the "Company"), a growing provider of software communications solutions, announced today that the election of Mr. Jason Cataldo as its President & Chief Executive Offer and Chairman of the Board of Directors. Mr. Cataldo succeeds Mr. Paul Phillips in the President & Chief Executive Officer and Chairman role to move the company into E-commerce and strong revenue generation.

The Company would like to thank Mr. Philips for his contributions and wish him good luck with his new endeavors. "I am honored to be appointed as the President & Chief Executive Officer and Chairman of the Telecorp Board of Directors during this pivotal point in the Company's evolution," said Mr. Cataldo. "Throughout 2015, Telecorp has executed effectively on achieving its key strategic goals, culminating in bringing revenues and the potential for significant value creation through its acquisitions in the web development space. We will now expand on our acquisitions to move into the highly profitable e-commerce business leaning on our expertise in the SEO, web development and online sales and marketing. Shareholders should expect news from the Company in the near future on the execution of our new strategy and new acquisition. I look forward to working with management and the Board to strengthen our standing as a leader in the field of web development and E-commerce, and to ensure the Company continues its record of execution, with the goal of maximizing shareholder value and moving to profitability in the near future."

Prior to Telecorp, Mr. Cataldo held management positions at Advanced Medical Care Group, JAC Group and CPG Financial. He has extensive experience in E-commerce, healthcare, finance, management and merger and acquisitions. Mr. Cataldo holds a BBA from Montclair State University in marketing and business management.

About Telecorp Inc.
Telecorp is an emerging provider of communication solutions to an array of companies and industries including, automotive, real estate, financial, health, charities, and many more. Telecorp offers creative software solutions for communicating with customers at levels never seen before. A total solution that is not only affordable, but indispensable for any business, no matter the size. Telecorp's modules allow the best marketing tools, first rate sales acquisition systems, customer communication processes, and drive greater profitability from every interaction, allowing every user to reduce costs and increase productivity at every use.

The Company's integrated suite of customized solutions includes, but is not limited to: customer acquisition, customer care, automated voice services, emergency communications, conferencing, data management, webinars, customer and hardware support tools, e-mail, fax and text broadcast messaging, direct to voice mail messaging, customized voice messaging, text to speech systems, predictive and progressive dialing, contact management solutions and much more.

Safe Harbor Statement
Except for historic information contained in this release, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, the company's ability to attract qualified management, raise sufficient capital to execute its business plan, and effectively compete against similar companies.

For further information, please contact:
Telecorp Inc.
Investor Relations: investors@telecorp.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Licensing Deal to Add Six Prescription Products with over 20 Billion dollars in Potential market size to GDAR Pipeline

San Diego, CA -- (ReleaseWire) -- 05/04/2016 -- Golden Age Resources Inc. (OTCPINK:GDAR), a leading acquisition and development company, announced today that it entered the highly profitable pharmaceutical business with the signing of a term sheet with Biopharma Pravo alpha for the perpetual exclusive worldwide rights for six products for a potential of 20 billion dollar markets. Under the terms of the signed term sheet, GDAR will have an exclusive perpetual pre-paid worldwide rights for the following products focusing on cardiovascular, anti-microbial, immunity and pain relief.

To view the chart please visit Uptick Newswire.

The Company expects to close the licensing deal in the upcoming weeks and will continue to update its shareholders on the progress. In connection with the change in direction, the Company announced the appointment of Mr. Daniel Kogan as the new President & Chief Executive Officer effective immediately. Mr. Kogan replaces Mr. Byrne who decided to pursue other opportunities. The Company would like to thank Mr. Byrne for his contributions and wish him good luck with his new endeavors.

"I am delighted to join GDAR as its President & CEO to build the new management team and execute on the Board's new direction to move the Company into the commercial stage and a positive cash flow situation in the near future" Said Mr. Kogan. "Once we complete the licensing agreement of the new products and start receiving approvals in the different territories, we expect to move to a cash flow positive situation very fast and turn the corner to profitability" continued Mr. Kogan.

Prior to GDAR, Mr. Kogan held management positions at Metlife and KOSH. He has extensive experience in finance, management and merger and acquisitions. Mr. Kogan holds an MBA from St. John's University / Peter J. Tobin College of Business.

About Golden Age Resources, Inc.
Headquartered in Pam Beach Gardens, GDAR plans to focus on the development of prescription and over the counter medicines in large therapeutics areas including, cardiovascular, antimicrobial, immunity, arthritis and pain among others.

For more information visit www.gdarinc.com

About Biopharma Pravo Alpha (BPA)
Biopharma Bravo Alpha (BBA) is a 15 year old Russian based fully integrated pharma leader in innovative and generic pharmaceuticals. The Company's vertical integration gives it the needed stability in a dynamic supply and business environment. The company has 15 drugs currently commercialized in Russia with Tubosan® to increase immunity as the lead product. In addition, the Company has an impressive pipeline of products at various stages of approval.

For more information visit www.alphabiopharma.com

Forward Looking Statements
This press release contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. There are no assurances that the Company will be able to sign and close the licensing agreement for the Products and even if the license agreement is signed, there is no assurance that the products will be approved in other territories. You should consider these factors in evaluating the statements herein and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Golden Age Resources, Inc. undertakes no obligation to update such statements.

Contact:
Daniel Kogan, President & CEO
ir@gdarinc.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm